Literature DB >> 34246086

The role of PAK4 in the immune system and its potential implication in cancer immunotherapy.

Azza Naїja1, Maysaloun Merhi2, Varghese Inchakalody2, Queenie Fernandes3, Sarra Mestiri2, Kirti S Prabhu4, Shahab Uddin5, Said Dermime6.   

Abstract

The p21 activated kinases (PAKs) are known to play a role in the regulation of cell morphology and functions. Among the various members of PAKs family, only the PAK4 protein has been shown to be overexpressed in cancer cells and its upregulation was associated with tumor development. Indeed, several studies have shown that PAK4 overexpression is implicated in carcinogenesis by different mechanisms including promotion of cell proliferation, invasion and migration, protection of cells from apoptosis, stimulation of the tumor-specific anchorage-independent cell growth and regulation of the cytoskeletal organisation and adhesion. Moreover, high PAK4 protein levels have been observed in several solid tumors and have been shown able to enhance cancer cell resistance to many treatments especially chemotherapy. Interestingly, it has been recently demonstrated that PAK4 downregulation can inhibit the PD-1/PD-L1 immune regulatory pathway. Taken together, these findings not only implicate PAK4 in oncogenic transformation and in prediction of tumor response to treatment but also suggest its role as an attractive target for immunotherapy. In the current review we will summarize the different mechanisms of PAK4 implication in tumor development, describe its role as a regulator of the immune response and as a potential novel target for cancer immunotherapy.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotherapy; PAK4; PD-1; Tumorigenesis

Mesh:

Substances:

Year:  2021        PMID: 34246086     DOI: 10.1016/j.cellimm.2021.104408

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  4 in total

Review 1.  The significance of PAK4 in signaling and clinicopathology: A review.

Authors:  Xinbo Yu; Changwei Huang; Jiyuan Liu; Xinyu Shi; Xiaodong Li
Journal:  Open Life Sci       Date:  2022-06-20       Impact factor: 1.311

2.  Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors.

Authors:  Fulai Gao; Jiaqi Wang; Changjuan Li; Changshun Xie; Miao Su; Chunyan Zou; Xiaoli Xie; Dongqiang Zhao
Journal:  Int J Gen Med       Date:  2022-04-08

Review 3.  Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents.

Authors:  Yang Li; Qing Lu; Chenghu Xie; Yiming Yu; Ao Zhang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

4.  Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.

Authors:  Rossella Bruno; Anello Marcello Poma; Greta Alì; Claudia Distefano; Agnese Proietti; Antonio Chella; Marco Lucchi; Franca Melfi; Renato Franco; Gabriella Fontanini
Journal:  Diagnostics (Basel)       Date:  2022-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.